Lab
Vanguard Laboratory Innovations
Vanguard Laboratory Innovations was paid $63K by Medicaid between Jun 2023 and Oct 2024, across 73 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 41% of everything it billed.
33Billing provider infoVANGUARD LABORATORY INNOVATIONS
TULSA, OK 74132
TULSA, OK 74132
33aNPI1770207607assigned 10/04/2022
33bProvider typeClinical Medical Laboratory
28Total paid$63K
24GClaims13,553
24DCodes billed73
24AFirst – last monthJun 2023 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Oklahoma
Rank by total paid#30 of 46
Median peer was paid$248K
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 3,616 | $37K | |
| 2024incomplete | 9,937 | $26K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 41% | 483 | 261 | $26K |
| 81419 | 25% | 266 | 262 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 8.9% | 680 | 584 | $6K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 91 | 68 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 399 | 303 | $934.24 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 337 | 331 | $774.23 |
| 81185 | 1.1% | 74 | 74 | $677.01 | |
| 83970 | <1% | 228 | 226 | $605.94 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 487 | 477 | $588.50 |
| 87481 | <1% | 553 | 472 | $496.37 | |
| 80053 | Comprehensive metabolic panel | <1% | 584 | 567 | $495.14 |
| 80061 | Lipid panel | <1% | 440 | 432 | $471.73 |
61 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 40 | $392.64 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 132 | $365.42 |
| 81181 | <1% | 267 | $354.36 | |
| 87486 | <1% | 61 | $350.89 | |
| 87541 | <1% | 61 | $350.89 | |
| 87581 | <1% | 61 | $350.89 | |
| 87500 | <1% | 555 | $347.27 | |
| 87653 | <1% | 524 | $343.30 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 508 | $324.75 |
| 87641 | <1% | 568 | $316.22 | |
| 84481 | <1% | 245 | $310.78 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 437 | $301.43 |
| 81286 | <1% | 12 | $275.73 | |
| 82607 | <1% | 156 | $267.60 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 154 | $266.68 |
| 84681 | <1% | 122 | $257.14 | |
| 87640 | <1% | 557 | $238.11 | |
| 86800 | <1% | 228 | $227.79 | |
| 84439 | <1% | 294 | $223.68 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 32 | $220.00 |
| 81189 | <1% | 76 | $219.86 | |
| 81309 | <1% | 35 | $219.86 | |
| 87631 | <1% | 29 | $219.84 | |
| 82533 | <1% | 151 | $212.77 | |
| 86376 | <1% | 227 | $212.08 | |
| 83090 | <1% | 80 | $202.70 | |
| 82746 | <1% | 93 | $188.51 | |
| 82172 | <1% | 136 | $180.05 | |
| 83525 | <1% | 165 | $161.64 | |
| 81339 | <1% | 17 | $148.16 | |
| 82728 | <1% | 107 | $140.13 | |
| 84466 | <1% | 73 | $137.00 | |
| 83721 | <1% | 81 | $103.60 | |
| 87529 | <1% | 360 | $85.16 | |
| 82977 | <1% | 110 | $81.26 | |
| 83540 | <1% | 93 | $66.39 | |
| 87556 | <1% | 43 | $66.35 | |
| 81430 | <1% | 23 | $65.00 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 347 | $60.46 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 353 | $56.19 |
| 82248 | <1% | 139 | $56.01 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 350 | $55.87 |
| 84550 | <1% | 146 | $47.28 | |
| 82043 | <1% | 12 | $22.85 | |
| 82570 | <1% | 12 | $20.70 | |
| 81479 | Unlisted molecular pathology procedure | <1% | 41 | $3.20 |
| 81001 | <1% | 28 | $2.49 | |
| 81254 | <1% | 23 | $1.40 | |
| 81226 | 0% | 76 | $0.00 | |
| 81225 | 0% | 50 | $0.00 | |
| 87511 | 0% | 33 | $0.00 | |
| 81250 | 0% | 14 | $0.00 | |
| 81162 | 0% | 17 | $0.00 | |
| 84153 | 0% | 15 | $0.00 | |
| 81344 | 0% | 12 | $0.00 | |
| 81343 | 0% | 12 | $0.00 | |
| 81312 | 0% | 12 | $0.00 | |
| 87563 | 0% | 273 | $0.00 | |
| 81321 | 0% | 29 | $0.00 | |
| 81364 | 0% | 12 | $0.00 | |
| 87150 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMYERS, CHRIS (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Hermes Health Labs | Scottsdale, AZ | $1.28M |
| No 206 LLC | Marina Del Rey, CA | $536.76 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.